Regulatory Filings • Dec 22, 2005
Regulatory Filings
Open in ViewerOpens in native device viewer
| C004 | ��� �� �� ������������� ��"� | 2 | |
| Public | X T L BIOPHARMACEUTICALS LTD | ||
| 4312 | Corporation no: 520039470 | ||
| Stock Exchange/Market: ��� �� �� | |||
| 1996 | |||
| 352 | Hasapir 3 , Nes Ziona 76100 , , | ||
| Tel: 08-9304444 , Fax: 08-9304445 | |||
| E.mail address: [email protected] | Date of transmission: 22/12/2005 | ||
| Time of broadcast: 09:31 09:31:04 | |||
| Reference: 2005-02-082791 | |||
| Israel Securities Authority | Tel Aviv Stock Exchange | |||||
| www.isa.gov.il | www.tase.co.il |
Immediate report on other matterDon't use this form if there is more adequate one
| CUBIST PHARMACEUTICALS REPORTS RESULTS FROM PHASE 2 STUDY HEPEX-B� , WHICH WAS LICENSED FROM XTLBIO |
| Attached file 26-05Cubist_Reports_Ph2_Results_HepB_22Dec05_isa.pdf |
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): |
| Previous names of reporting entity: XENOGRAFT TECHNOLOGIES LTD |
| Date of revision of form structure: 01/12/2005 |
| - - - |
| Name of the Signatory : Burgin Jonathan , , Position of Signatory in the reporting corporation: Chief Financial Officer |
| Hasapir Telephone: 08-9304440 , Facsimile: 08-9300659 , E-mail: [email protected] |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.